Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma

  • End date
    Sep 20, 2034
  • participants needed
  • sponsor
    Oslo University Hospital
Updated on 20 September 2021
ct scan
platelet count
neutrophil count
cancer chemotherapy
soft tissue sarcoma
synovial sarcoma
undifferentiated pleomorphic sarcoma
malignant peripheral nerve sheath tumor


Nearly half of patients with high-grade, localized soft tissue sarcoma (STS) of extremities and trunk wall develop disease recurrence after local therapy. Adjuvant chemotherapy with ifosfamide and doxorubicin may improve long-term disease-free survival, but the benefit of adjuvant treatment is limited and predictive factors for treatment response are lacking. The aim of this study is to explore sequential treatment with ifosfamide and doxorubicin in a neoadjuvant setting and to investigate biomarkers predictive of treatment response.

Condition Connective and Soft Tissue Neoplasm, Sarcoma, All Solid Tumors, Solid Tumors, Sarcoma (Pediatric), Soft Tissue Sarcoma, sarcomas, soft tissue sarcomas
Treatment ifosfamide, doxorubicin
Clinical Study IdentifierNCT04776525
SponsorOslo University Hospital
Last Modified on20 September 2021


Yes No Not Sure

Inclusion Criteria

18 years of age at the time of informed consent
Histological diagnosis of soft tissue sarcoma belonging to one of the following
Malignant peripheral nerve sheath tumor
Undifferentiated pleomorphic sarcoma
Synovial sarcoma
Pleomorphic liposarcoma
Pleomorphic rhabdomyosarcoma
Unclassified spindle cell sarcoma
Malignancy grade 2 according to the Fdration Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grading system
Tumor localized in extremity, girdle and/or trunk wall
Primary tumor size 5.0 cm as measured in the longest diameter on diagnostic MRI or CT scan
Primary tumor location below the superficial fascia or involving the superficial fascia, i.e. deep-seated according to the World Health Organization (WHO) Classification of Tumors of Soft Tissue and Bone (4th edition, 2013)
The primary tumor must be available for biopsy collection at protocol inclusion
Patients must have a measurable tumor according to RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Before patient registration, written informed consent must be given according to national and local regulations
Adequate organ function and bone marrow reserve as indicated by the following laboratory assessments
Hemoglobin 8.0 g/dL
Neutrophil count 1.0 x 109/L
Platelet count 75 x 109/L
Total bilirubin 1.5 x the upper limit of normal (ULN)
Creatinine clearance 60 ml/min based on Cockcroft Gault estimation or direct measurement
Negative Hepatitis B and C and HIV serology
Adequate contraception in women of childbearing potential (WOCBP) and their fertile partners during the study and until 6 months after end of study treatment. WOCBP should have a negative highly sensitive serum or urine pregnancy test within 72 hours prior to receiving the first dose of study medication. A woman is considered fertile following menarche and until becoming post-menopausal unless permanently sterile. WOCBP should be willing to use one of the mentioned highly effective methods of birth control mentioned below or be surgically sterile, or abstain from heterosexual activity for the course of the study through 1 year after the last dose of study medication. Methods considered as highly effective birth control methods include combined (estrogen and progestogen containing) or progestogen-only hormonal contraception associated with inhibition of ovulation (oral, intravaginal, injectable, implantable or transdermal), intrauterine device (including hormone-releasing), male condom, bilateral tubal occlusion, vasectomised partner or sexual abstinence (see appendix 5 for definitions)

Exclusion Criteria

Any prior therapy for soft tissue sarcoma
Locoregional or distant metastasis as assessed by CT and/or MRI at time of diagnosis. Patients with lung nodules <10 mm of uncertain etiology may be included
Clinical evidence of serious coagulopathy. Prior arterial/venous thrombosis or embolism does not exclude patients from inclusion, unless patient is considered unfit by study oncologist
Urinary obstruction
Known hypersensitivity towards ifosfamide, doxorubicin or pegfilgrastim, their metabolites and other ingredients in the drug administration formulation
New York Heart Association class II-IV heart disease, myocardial infarction within 6 months of diagnosis of soft tissue sarcoma, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension or congestive heart failure
Left ventricular ejection fraction (LVEF) < 50%
Patients with a prior or concurrent malignant disease whose natural history or treatment have the potential to interfere with the safety or efficacy assessment of this clinical trial are not eligible. Patients with a history of breast cancer, requiring continued hormonal treatment (e.g. anti-estrogen or an aromatase inhibitor) may be included. Patients with a history of prostate cancer, requiring continued support with luteinizing hormone releasing hormone (LHRH) agonists, with or without androgens, may be included
Patients not able to give an informed consent or comply with study regulations as deemed by study investigator
Any other significant comorbidities, such as active infection, uncontrolled pulmonary or liver disease, active cystitis, or any other condition, that based on the assessment of the treating physician could compromise compliance with the protocol or predispose the patient to safety risks
Pregnant or lactating patients
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note